Spotlight On Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is a heterogeneous hematologic malignancy with a variable clinical course, presenting distinct challenges in risk assessment, treatment selection, and long-term disease management. And as advances in molecular profiling and targeted therapies continue to reshape the standard of care, clinicians must make increasingly nuanced decisions to address individual patient needs.
To help clinicians navigate these complexities, our Spotlight On Chronic Lymphocytic Leukemia series shares expert perspectives on the latest developments and care considerations, from the role of prognostic biomarkers to emerging therapeutic approaches.

CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Project Oncology®CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL

Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
Project Oncology®Ibrutinib-Venetoclax in Relapsed CLL: MRD-Guided Approach Balances Efficacy and Safety
- advertisement



